WO2007002174A3 - A method of treatment of hormone depletion induced vasomotor symptoms - Google Patents

A method of treatment of hormone depletion induced vasomotor symptoms Download PDF

Info

Publication number
WO2007002174A3
WO2007002174A3 PCT/US2006/024111 US2006024111W WO2007002174A3 WO 2007002174 A3 WO2007002174 A3 WO 2007002174A3 US 2006024111 W US2006024111 W US 2006024111W WO 2007002174 A3 WO2007002174 A3 WO 2007002174A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasomotor symptoms
treatment
depletion induced
hormone depletion
induced vasomotor
Prior art date
Application number
PCT/US2006/024111
Other languages
French (fr)
Other versions
WO2007002174A2 (en
Inventor
Edward Baker
Original Assignee
Organon Nv
Edward Baker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv, Edward Baker filed Critical Organon Nv
Priority to EP06773670A priority Critical patent/EP1898919A2/en
Priority to US11/917,456 priority patent/US20090306046A1/en
Publication of WO2007002174A2 publication Critical patent/WO2007002174A2/en
Publication of WO2007002174A3 publication Critical patent/WO2007002174A3/en
Priority to US13/471,631 priority patent/US20120245146A1/en
Priority to US13/722,507 priority patent/US20130116242A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for a limited period of a duration between 3 and 8 months.
PCT/US2006/024111 2005-06-27 2006-06-21 A method of treatment of hormone depletion induced vasomotor symptoms WO2007002174A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06773670A EP1898919A2 (en) 2005-06-27 2006-06-21 A method of treatment of hormone depletion induced vasomotor symptoms
US11/917,456 US20090306046A1 (en) 2005-06-27 2006-06-21 Method of treatment of hormone depletion induced vasomotor symptoms
US13/471,631 US20120245146A1 (en) 2005-06-27 2012-05-15 Method of treatment of hormone depletion induced vasomotor
US13/722,507 US20130116242A1 (en) 2005-06-27 2012-12-20 Method of treatment of hormone depletion induced vasomotor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69435505P 2005-06-27 2005-06-27
US60/694,355 2005-06-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11917456 Continuation 2007-12-13
US13/471,631 Continuation US20120245146A1 (en) 2005-06-27 2012-05-15 Method of treatment of hormone depletion induced vasomotor

Publications (2)

Publication Number Publication Date
WO2007002174A2 WO2007002174A2 (en) 2007-01-04
WO2007002174A3 true WO2007002174A3 (en) 2007-02-15

Family

ID=37398747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024111 WO2007002174A2 (en) 2005-06-27 2006-06-21 A method of treatment of hormone depletion induced vasomotor symptoms

Country Status (2)

Country Link
EP (1) EP1898919A2 (en)
WO (1) WO2007002174A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011434A (en) * 2006-03-06 2008-11-18 Organon Nv An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051111A1 (en) * 2004-11-15 2006-05-18 N.V. Organon S-mirtazapine for the treatment of hot flush

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051111A1 (en) * 2004-11-15 2006-05-18 N.V. Organon S-mirtazapine for the treatment of hot flush

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERENDSEN H H G: "HOT FLUSHES AND SEROTONIN", JOURNAL OF THE BRITISH MENOPAUSE SOCIETY, BRITISH MENOPAUSE SOCIETY, MARLOW, GB, vol. 8, no. 1, March 2002 (2002-03-01), pages 30 - 34, XP009022459, ISSN: 1362-1807 *
GRADY DEBORAH ET AL: "Predictors of difficulty when discontinuing postmenopausal hormone therapy.", OBSTETRICS & GYNECOLOGY, vol. 102, no. 6, December 2003 (2003-12-01), pages 1233 - 1239, XP002408093, ISSN: 0029-7844 *
MALAGUENO ET AL: "New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 809, October 2004 (2004-10-01), pages 351 - 356, XP002310476, ISSN: 1570-0232 *
PEREZ D G ET AL: "PILOT EVALUATION OF MIRTAZAPINE FOR THE TREATMENT OF HOT FLASHES", JOURNAL OF SUPPORTIVE ONCOLOGY, BIOLINK COMMUNICATIONS,, US, vol. 2, no. 1, February 2004 (2004-02-01), pages 50 - 56, XP001204198, ISSN: 1544-6794 *
WALDINGER M D ET AL: "TREATMENT OF HOT FLUSHES WITH MIRTAZAPINE: FOUR CASE REPORTS", MATURITAS, ELSEVIER SCIENCE PUBLISHERS IRELAND LTD, IR, vol. 36, no. 3, 2000, pages 165 - 168, XP000997878, ISSN: 0378-5122 *

Also Published As

Publication number Publication date
WO2007002174A2 (en) 2007-01-04
EP1898919A2 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2009093119A3 (en) Use of serine protease inhibitors in the treatment of skin diseases
MX2011007854A (en) Methods for treating acute myocardial infarctions and associated disorders.
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
MX2009011540A (en) Treatment of movement disorders by a combined use of botulinum toxin and muscle stimulation.
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
IN2015DN04175A (en)
CA2632207C (en) Use of calcitonin for the treatment of ra
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2007110871A3 (en) Methods and composition for treating sore throat
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
MX2007010886A (en) Acarbose methods and formulations for treating chronic constipation.
WO2007047205A3 (en) Enzyme inhibitors of pai-1
WO2007143185A3 (en) Transdermal treatment of tendinopathy using glyceryl trinitrite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 11917456

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006773670

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE